Clinical Oncology
Volume 18, Issue 2 , Pages 155-156 , March 2006

Three Cases of Activation of Cutaneous Squamous-cell Carcinoma During Treatment with Prolonged Administration of Rituximab

  • G.B. Fogarty

      Affiliations

    • Radiation Oncology, Mater Hospital, Sydney, Australia
    • ,
  • M. Bayne

      Affiliations

    • Radiation Oncology, Peter MacCallum Cancer Centre, Melbourne, Australia
    • ,
  • P. Bedford

      Affiliations

    • Pathology, St John of God Hospital, Ballarat, Australia
    • ,
  • R. Bond

      Affiliations

    • Ballarat Oncology Services, Ballarat, Australia
    • ,
  • G. Kannourakis

      Affiliations

    • Ballarat Oncology Services, Ballarat, Australia

Received 3 November 2005 ,Accepted 9 November 2005.

References 

  1. Hemminki K, Jiang Y, Steineck G. Skin cancer and non-Hodgkin's lymphoma as second malignancies: markers of impaired immune function. Eur J Cancer. 2003;39:223–229
  2. Maloney DG, Smith B, Rose A. Rituximab: mechanism of action and resistance. Semin Oncol. 2002;29(1 Suppl 2):S2–S9
  3. Grillo-Lopez AJ. Rituximab: the first decade (1993–2003). Expert Rev Anticancer Ther. 2003;3:767–779
  4. Walewski J, Kraszewska E, Mioduszewska O, et al. Rituximab in patients with recurrent indolent lymphoma: evaluation of safety and efficacy in a multicenter study. Med Oncol. 2001;18:141–148
  5. Singh R, Robinson DB, El-Gabalawy HS. Emerging biologic therapies in rheumatoid arthritis: cell targets and cytokines. Curr Opin Rheumatol. 2005;17:274–279
  6. Chaiwatanatorn K, Lee N, Grigg A, et al. Delayed-onset neutropenia associated with rituximab therapy. Br J Haematol. 2003;121:913–918
  7. Tsutsumi Y, Kanamori H, Mori A, et al. Reactivation of hepatitis B virus with rituximab. Expert Opin Drug Saf. 2005;4:599–608

PII: S0936-6555(05)00452-8

doi: 10.1016/j.clon.2005.11.015

Clinical Oncology
Volume 18, Issue 2 , Pages 155-156 , March 2006

Article Tools

* Image Usage & Resolution